IRIS
CIMADAMORE, Alessia
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 12.016
AS - Asia 4.003
EU - Europa 2.955
SA - Sud America 722
AF - Africa 301
Continente sconosciuto - Info sul continente non disponibili 236
OC - Oceania 8
Totale 20.241
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 11.880
SG - Singapore 1.614
RU - Federazione Russa 766
VN - Vietnam 696
CN - Cina 626
BR - Brasile 554
HK - Hong Kong 518
IT - Italia 476
IE - Irlanda 434
SE - Svezia 259
DE - Germania 242
FR - Francia 222
CI - Costa d'Avorio 191
GB - Regno Unito 178
IN - India 139
UA - Ucraina 120
BD - Bangladesh 76
FI - Finlandia 65
JP - Giappone 51
CA - Canada 50
AR - Argentina 49
MX - Messico 45
CO - Colombia 42
NL - Olanda 35
ZA - Sudafrica 34
PL - Polonia 32
IQ - Iraq 30
KR - Corea 30
TR - Turchia 27
ID - Indonesia 26
MA - Marocco 24
ES - Italia 23
PH - Filippine 23
EC - Ecuador 21
PK - Pakistan 21
BE - Belgio 19
VE - Venezuela 19
UZ - Uzbekistan 18
MY - Malesia 14
EE - Estonia 13
DK - Danimarca 12
CL - Cile 11
EG - Egitto 11
SA - Arabia Saudita 11
TN - Tunisia 11
TH - Thailandia 9
AU - Australia 8
BO - Bolivia 8
IL - Israele 8
JO - Giordania 8
KZ - Kazakistan 8
BG - Bulgaria 7
PY - Paraguay 7
RO - Romania 7
UY - Uruguay 7
AT - Austria 6
CR - Costa Rica 6
CZ - Repubblica Ceca 6
AE - Emirati Arabi Uniti 5
DO - Repubblica Dominicana 5
DZ - Algeria 5
HN - Honduras 5
KG - Kirghizistan 5
LB - Libano 5
NP - Nepal 5
TT - Trinidad e Tobago 5
AZ - Azerbaigian 4
ET - Etiopia 4
KE - Kenya 4
LT - Lituania 4
NI - Nicaragua 4
OM - Oman 4
PA - Panama 4
AL - Albania 3
AO - Angola 3
BH - Bahrain 3
CH - Svizzera 3
GA - Gabon 3
GT - Guatemala 3
LU - Lussemburgo 3
LY - Libia 3
PE - Perù 3
PS - Palestinian Territory 3
SK - Slovacchia (Repubblica Slovacca) 3
SY - Repubblica araba siriana 3
AM - Armenia 2
BA - Bosnia-Erzegovina 2
GD - Grenada 2
GE - Georgia 2
HR - Croazia 2
HU - Ungheria 2
IS - Islanda 2
KH - Cambogia 2
PR - Porto Rico 2
RS - Serbia 2
SN - Senegal 2
SV - El Salvador 2
ZW - Zimbabwe 2
AD - Andorra 1
BB - Barbados 1
Totale 19.985
Salva come PNG Salva come JPEG
Città #
Ashburn 1.793
Des Moines 1.473
Singapore 1.196
Chandler 1.178
Fairfield 666
Dallas 571
San Jose 534
Hong Kong 505
Dublin 425
Wilmington 347
Council Bluffs 330
Boardman 324
Woodbridge 282
Houston 261
Seattle 256
The Dalles 246
Ho Chi Minh City 224
Cambridge 214
Jacksonville 200
Abidjan 191
New York 170
Lawrence 167
Princeton 167
Beijing 160
Lauterbourg 158
Los Angeles 154
Hanoi 150
San Mateo 142
Ann Arbor 135
Moscow 128
San Diego 102
Munich 81
Washington 73
Redmond 72
Pune 65
Milan 61
Santa Clara 59
Columbus 55
São Paulo 55
London 48
Chicago 47
Orem 45
Tokyo 44
Hefei 40
Helsinki 40
Da Nang 36
Haiphong 36
Ancona 34
Miano 34
Shanghai 32
Buffalo 31
Falls Church 31
Rome 30
Wuhan 29
Warsaw 27
Brooklyn 25
Frankfurt am Main 24
Guangzhou 24
Phoenix 24
Turku 24
Manchester 23
Montreal 23
Stockholm 22
Atlanta 21
Denver 21
San Francisco 20
Turin 20
Brussels 19
Norwalk 19
Chennai 18
Amsterdam 17
Seoul 17
Dhaka 16
Mexico City 16
Tashkent 16
Jiaxing 15
Rio de Janeiro 15
Boston 13
Brasília 13
Can Tho 13
Johannesburg 12
Poplar 12
Baghdad 11
Curitiba 11
Jakarta 11
Medellín 11
Porto Alegre 11
Bogotá 10
Cape Town 10
Hải Dương 10
Prescot 10
Salt Lake City 10
Thái Nguyên 10
Toronto 10
Bologna 9
Elk Grove Village 9
Forlì 9
Istanbul 9
Tampa 9
Amman 8
Totale 14.634
Salva come PNG Salva come JPEG
Nome #
Questioning the prognostic role of BAP-1 immunohistochemistry in malignant pleural mesothelioma: A single center experience with systematic review and meta-analysis 229
Immunotherapy in genitourinary cancers: Where are we going? 211
Sequential or Concomitant Inhibition of Cyclin-Dependent Kinase 4/6 Before mTOR Pathway in Hormone-Positive HER2 Negative Breast Cancer: Biological Insights and Clinical Implications 204
Designing novel immunocombinations in metastatic renal cell carcinoma 204
BRCA-associated protein 1 (BAP1) and miR-31 combination predicts outcomes in epithelioid malignant pleural mesothelioma 203
Biomarkers of angiogenesis and clinical outcomes to Cabozantinib and Everolimus in Patients with Metastatic Renal Cell Carcinoma from the Randomized Phase III METEOR Trial 203
Are liver nested stromal epithelial tumors always low aggressive? 202
Predicting future cancer burden in the United States by artificial neural networks 200
Androgen Receptor Signaling Pathway in Prostate Cancer: From Genetics to Clinical Applications 187
Biological issues with cabozantinib in bone metastatic renal cell carcinoma and castration-resistant prostate cancer 179
Biomarkers of aggressiveness in genitourinary tumors with emphasis on kidney, bladder, and prostate cancer 175
Exploring the Spectrum of Kidney Ciliopathies 172
The Role of Artificial Intelligence in the Diagnosis and Prognosis of Renal Cell Tumors 172
Activity of chemokines in prostate and renal tumors and their potential role as future therapeutic targets 165
Adjuvant and neoadjuvant approaches for urothelial cancer: Updated indications and controversies 163
Germline and somatic mutations in prostate cancer: Focus on defective DNA repair, PARP inhibitors and immunotherapy 161
An update on investigational therapies that target STAT3 for the treatment of cancer 160
Microbiome and cancers, with focus on genitourinary tumors 158
Morphologic, Molecular and Clinical Features of Aggressive Variant Prostate Cancer 158
Contemporary best practice in the management of urothelial carcinomas of the renal pelvis and ureter 156
Detection limits of significant prostate cancer using multiparametric MR and digital rectal examination in men with low serum PSA: Up-date of the Italian Society of Integrated Diagnostic in Urology 154
Morphologic Variants of Epithelial and Neuroendocrine Tumors of the Prostate. The Pathologist's Point of View 153
Molecular characterization of testicular germ cell tumors using tissue microdissection 150
The role of obesity in renal cell carcinoma patients: Clinical-pathological implications 149
Bone targeting agents in patients with metastatic prostate cancer: State of the art 148
Added Clinical Value of Whole-mount Histopathology of Radical Prostatectomy Specimens: A Collaborative Review 148
Resistance to systemic agents in renal cell carcinoma predict and overcome genomic strategies adopted by tumor 147
Adjuvant therapy in renal cell carcinoma: Is it the right strategy to inhibit VEGF? 147
Is There a Role for Immunotherapy in Prostate Cancer? 145
An evaluation of current prostate cancer diagnostic approaches with emphasis on liquid biopsies and prostate cancer 142
The 1996 European Urology Focus on Preneoplastic Lesions of the Prostate 142
Narrative review of prostate cancer grading systems: Will the Gleason scores be replaced by the grade groups? 142
Pd-l1 inhibitors for the treatment of prostate cancer 141
Contemporary grading of prostate cancer: 2017 update for pathologists and clinicians 139
Targeted therapy for solid tumors and risk of hypertension: a meta-analysis of 68077 patients from 93 phase III studies 139
Molecular diagnostics in uro-oncology 139
Emerging prognostic biomarkers in testicular germ cell tumors: Looking beyond established practice 139
Current and emerging bladder cancer biomarkers with an emphasis on urine biomarkers 138
Real-world data on cabozantinib in previously treated patients with metastatic renal cell carcinoma: Focus on sequences and prognostic factors 136
Surgical pathology of cystic renal cell carcinomas: is there an overestimation of malignancy? 136
Predicting biochemical recurrence after radical prostatectomy: the role of prognostic grade group and index tumor nodule 136
Epigenetic modifications and modulators in prostate cancer 135
Variants and Variations in Epithelial Renal Cell Tumors in Adults: The Pathologist's Point of View 133
Clinicopathologic analysis of upper urinary tract carcinoma with variant histology 133
Inguinal bladder hernia with lipomatosis of the bladder wall: A potential clinical pitfall for cancer 133
The identification of immunological biomarkers in kidney cancers 133
Vascular Enlargement as a Predictor of Nodal Involvement in Bladder Cancer 132
Combining radiotherapy with immunocheckpoint inhibitors or CAR-T in Renal Cell Carcinoma 132
Predicting outcomes in non-muscle invasive (Ta/T1) bladder cancer: the role of molecular grade based on luminal/basal phenotype 132
RAS genes in colorectal carcinoma: Pathogenesis, testing guidelines and treatment implications 131
An insight on novel molecular pathways in metastatic prostate cancer: A focus on ddr, msi and akt 131
Combination therapy in advanced urothelial cancer: the role of PARP, HER-2 and mTOR inhibitors 130
Immunotherapy in renal cell carcinoma: latest evidence and clinical implications 129
Body Mass Index in Patients Treated with Cabozantinib for Advanced Renal Cell Carcinoma: A New Prognostic Factor? 129
pT1 high-grade bladder cancer: histologic criteria, pitfalls in the assessment of invasion, and substaging 128
From undergraduate medical school student to visible pathologist 128
The human microbiota and prostate cancer: Friend or foe? 127
Expression of miR-100 and miR-138 as prognostic biomarkers in non-muscle-invasive bladder cancer 127
p53, cathepsin D, Bcl-2 are joint prognostic indicators of breast cancer metastatic spreading 127
Key role of obesity in genitourinary tumors with emphasis on urothelial and prostate cancers 126
Genitourinary tumors: Update on molecular biomarkers for diagnosis, prognosis and prediction of response to therapy 125
Current application of the enhanced recovery after surgery protocol for patients undergoing radical cystectomy: lessons learned from European excellence centers 125
Biphasic Tumors of the Urogenital Tract: Selected Topics 125
Pathology and molecular updates in tumors of the prostate: towards a personalized approach. 124
An update on immunotherapy in uro-oncology 124
Immune checkpoint inhibitors for the treatment of bladder cancer 124
Biomarkers of Angiogenesis and Clinical Outcomes to Cabozantinib and Everolimus in Patients with Metastatic Renal Cell Carcinoma from the Phase III METEOR Trial 124
Clinical Actionability of the Genomic Landscape of Metastatic Castration Resistant Prostate Cancer 123
Extramammary Paget disease of the penis closely mimicking the penile analogue of stratified mucin-producing intraepithelial lesion 123
Novel Therapeutic Approaches and Targets Currently Under Evaluation for Renal Cell Carcinoma: Waiting for the Revolution 123
Immunotherapy in renal cell carcinoma from poverty to the spoiled of choice 122
Prostate cancer with cribriform morphology: diagnosis, aggressiveness, molecular pathology and possible relationships with intraductal carcinoma 122
Syndrome of inappropriate antidiuresis in prostate adenocarcinoma with neuroendocrine differentiation: a case report and literature review 121
Liquid biopsy in the clinical management of bladder cancer: current status and future developments 121
Prostate cancer grading in 2018: Limitations, implementations, cribriform morphology, and biological markers 121
Grading of Chromophobe Renal Cell Carcinoma: Do We Need It? 121
Variants of Bladder Cancer: The Pathologist's Point of View 120
Circulating tumor dna testing for homology recombination repair genes in prostate cancer: From the lab to the clinic 120
Renal Cell Carcinoma: genomic landscape and clinical implications 119
New prostate cancer targets for diagnosis, imaging, and therapy: Focus on prostate-specific membrane antigen 118
Exploring small extracellular vesicles for precision medicine in prostate cancer 115
PreImplantation Factor immunohistochemical expression correlates with prostate cancer aggressiveness 115
Variants and new entities of bladder cancer 115
Epigenetic modulations and lineage plasticity in advanced prostate cancer 115
Pathology without microscope: From a projection screen to a virtual slide 115
Agent-Based Learning Model for the Obesity Paradox in RCC 114
Molecular Pathology of Urothelial Carcinoma 114
Treating prostate cancer by antibody-drug conjugates 114
Prostate cancer in 2021: Novelties in prognostic and therapeutic biomarker evaluation 114
Accuracy of the CUETO, EORTC 2016 and EAU 2021 scoring models and risk stratification tables to predict outcomes in high-grade non-muscle-invasive urothelial bladder cancer 113
Long Non-coding RNAs in prostate cancer with emphasis on second chromosome locus associated with prostate-1 expression 112
TNM staging towards a personalized approach in metastatic urothelial carcinoma: What will the future be like?-a narrative review 112
Narrative review: Predicting future molecular and clinical profiles of prostate cancer in the United States 112
Incorporating Prognostic Biomarkers into Risk Assessment Models and TNM Staging for Prostate Cancer 111
Digital versus light microscopy assessment of extraprostatic extension in radical prostatectomy samples 111
New Frontiers in Prostate Cancer Treatment: Are We Ready for Drug Combinations with Novel Agents? 110
PD1 and PD-L1 Inhibitors for the Treatment of Kidney Cancer: the Role of PD-L1 Assay 110
Considerations on current and future issues related to reproducibility and accuracy in prostate cancer grading 110
Update on Prostate Cancer Diagnosis, Prognosis, and Prediction to Response to Therapy 110
Digital frozen section of the prostate surface during radical prostatectomy: a novel approach to evaluate surgical margins 110
Totale 13.845
Salva come PNG Salva come JPEG
Categoria #
all - tutte 105.433
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 105.433
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.245 0 171 79 23 50 179 28 90 128 116 87 294
2022/20234.130 266 288 156 313 218 1.705 3 234 680 16 178 73
2023/20241.610 282 45 138 162 248 358 22 49 5 57 24 220
2024/20252.948 376 229 35 52 103 121 226 107 750 305 259 385
2025/20267.265 396 441 441 288 1.024 469 1.490 741 733 669 178 395
2026/2027396 192 204 0 0 0 0 0 0 0 0 0 0
Totale 20.241